

- **Name:** **Ji-Yeon Kim**
- **Current Position & Affiliation:** **Assistant professor & Samsung Medical Center**
- **Country:** **Korea**

• **Educational Background:**

Institution and Location	Degree	Year Conferred	Field of Study
College of Medicine, Seoul National University Seoul, Korea	M.D.	2008	Medicine
College of Medicine, Seoul National University Seoul, Korea	PhD	2012.3-2020.2	Medicine, Molecular and Clinical Oncology Major

• **Professional Experience:**

Institution and Location	Degree	Year Conferred	Field of Study
Seoul National University Hospital, Seoul, Korea	Internship & Residency	2013	Dept. of Internal Medicine
Seoul National University Hospital, Seoul, Korea	Fellowship	2013.3-2015.2	Dept. of Internal Medicine, Division of Hematology-Oncology
Samsung Medical Center	Clinical assistant professor	2015.3-2020.2	Dept. of Internal Medicine, Division of Hematology-Oncology, Breast Cancer Center
Samsung Medical Center	Assistant professor	2020.3-	Dept. of Internal Medicine, Division of Hematology-Oncology, Breast Cancer Center

• **Professional Organizations:**

• **Main Scientific Publications:**

1. **Kim JY**, Ok ON, Seo JJ, Lee SH, Ahn JS, Im YH, et al. A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy. *Breast Cancer Res Treat.* 2017.
2. **Kim JY**, Lee E, Park K, Park WY, Jung HH, Ahn JS, et al. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes. *Oncotarget.* 2017;8(17):27997-8007.
3. Park S, **Kim JY**, Lee SH, Suh B, Keam B, Kim TM, et al. KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. *Korean J Intern Med.* 2017;32(3):514-22.
4. **Kim JY**, Park D, Son DS, Nam SJ, Kim SW, Jung HH, et al. Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy. *Oncotarget.* 2017;8(49):86423-34.
5. **Kim JY**, Yu JH, Nam SJ, Kim SW, Lee SK, Park WY, et al. Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast. *Transl Oncol.* 2018;11(1):18-23.
6. **Kim JY**, Lim JE, Jung HH, Cho SY, Cho EY, Lee SK, et al. Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort. *Breast Cancer Res Treat.* 2018;171(3):737-45.
7. **Kim JY**, Im SA, Jung KH, Ro J, Sohn J, Kim JH, et al. Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). *Eur J Cancer.* 2018;103:127-36.
8. **Kim JY**, Lee E, Park K, Jung HH, Park WY, Lee KH, et al. Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients. *Int J Cancer.* 2019;145(6):1669-78.
9. **Kim JY**, Park S, Im SA, Kim SB, Sohn J, Lee KS, et al. Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11). *Cancer Commun (Lond).* 2019;39(1):29.
10. **Kim JY**, Kang D, Nam SJ, Kim SW, Lee JE, Yu JH, et al. Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry. *J Glob Oncol.* 2019;5:1-9.
11. **Kim JY**, Lee E, Park K, Im SA, Sohn J, Lee KS, et al; Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11). *Breast Cancer Res Treat.* 2019 Aug 12. doi: 10.1007/s10549-019-05400-y. [Epub ahead of print] PubMed PMID: 31407230.